1213P DKN-01 and tislelizumab + chemotherapy as first-line (1L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
| Autor: | Klempner, S.J., Chao, J., Uronis, H., Sirard, C., Kagey, M., Baum, J., Song, J., Wang, J., Sonbol, M.B., Wainberg, Z.A., Ajani, J.A. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S1103-S1104 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|